Special Issues
Table of Content

Molecular Mechanisms of Urogenital Cancers

Submission Deadline: 31 August 2025 (closed) View: 1225 Submit to Journal

Guest Editors

Dr. Giovanni Tossetta

Email: g.tossetta@univpm.it

Affiliation: Department of experimental and clinical medicine, Faculty of Medicine and Surgery, Università Politecnica delle Marche, Ancona, Italy

Homepage:

Research Interests: Endometriosis, Endometrial cancers, Ovarian Cancer, Immunofluorescence Staining, Colon Cancer, Signalling, Western Blot, Cytokines, Immunohistochemistry, ELISA, Cell Culture, Real-Time PCR


Dr. Sonia Fantone

Email: s.fantone@inrca.it

Affiliation: Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, Ancona, Italy

Homepage:

Research Interests: Cell Culture, Immunohistochemistry, Quantitative Western Blot, Immunofluorescence - Immunofluorescence, Molecular Biology, Anatomy, Oxidative stress, Cancer, Aging, Senescence, Inflammation, Ovarian cancer, Prostate cancer, Antioxidants



Summary


The occurrence of urological cancers has significantly increased over the past 50 years but, despite advances in medical tumor therapy, the occurrence of chemotherapy resistance and metastatic disease is still a common cause of death in patients affected by these types of malignancies. For these reasons, it is necessary to develop and study new therapeutic approaches that can improve the diagnosis and treatment of urogenital cancer in order to improve the outcome of these malignancies. To this aim, we need a better understanding of the molecular mechanisms occurring in urological malignancies in order to develop new and efficient molecular biomarkers able to predict tumor behavior and risk of disease recurrence and chemoresistance.


This Special Issue of Oncology Research, therefore, welcomes original research articles and reviews related to the molecular mechanisms of urogenital cancers. 


Keywords

Prostate cancer; Bladder cancer; Renal cell carcinoma; Testicular cancer; Cancer biomarker; Diagnosis; Therapy; Treatments

Published Papers


  • Open Access

    ARTICLE

    ONX-0914 Suppresses Hormone-Sensitive Prostate Cancer by Promoting O-GlcNAcylation-Mediated Stabilization of TCF7L1

    Peng Xian, Zhenwei Feng, Haitao Yu, Hubin Yin, Haonan Chen, Tenglin Shi, Xilai Li, Chunlin Zhang, Xuesong Bai, Xin Gou, Xinyuan Li, Jie Li
    Oncology Research, DOI:10.32604/or.2026.073156
    (This article belongs to the Special Issue: Molecular Mechanisms of Urogenital Cancers)
    Abstract Objective: Androgen receptor (AR) signaling is a central driver of prostate cancer progression, yet the metabolic and transcriptional mechanisms regulating AR expression remain incompletely characterized. This study investigated whether the immunoproteasome inhibitor ONX-0914 suppresses hormone-sensitive prostate cancer (HSPC) through metabolic modulation of AR and aimed to identify the transcriptional mediator involved. Methods: HSPC and castration-resistant prostate cancer models were used to evaluate the effects of ONX-0914 on cell proliferation, invasion, migration, and epithelial–mesenchymal transition. Xenograft assays, bioinformatic screening, and analyses of O-GlcNAcylation and protein stability were performed, together with quantitative polymerase chain reaction (qPCR) and… More >

Share Link